Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

John B Porter

Showing results (81-90 of 125) with videos related to

Pageof 13
Sort By:
British Journal of Haematology|September 13, 2014
Defining serum ferritin thresholds to predict clinically relevant liver iron concentrations for guiding deferasirox therapy when MRI is unavailable in patients with non-transfusion-dependent thalassaemiaAli T Taher, John B Porter, Vip Viprakasit, et al.
Health and Quality of Life Outcomes|November 21, 2018
Patient-reported outcomes from a randomized phase II study of the deferasirox film-coated tablet in patients with transfusion-dependent anemiasAli T Taher, Raffaella Origa, Silverio Perrotta, et al.
European Journal of Haematology|January 28, 2014
Approaching low liver iron burden in chelated patients with non-transfusion-dependent thalassemia: the safety profile of deferasiroxAli T Taher, John B Porter, Vip Viprakasit, et al.
American Journal of Hematology|October 28, 2014
Sustained improvements in myocardial T2* over 2 years in severely iron-overloaded patients with beta thalassemia major treated with deferasirox or deferoxamineDudley J Pennell, John B Porter, Antonio Piga, et al.
Scientific Reports|February 28, 2017
Non-invasive MRI biomarkers for the early assessment of iron overload in a humanized mouse model of β-thalassemiaLaurence H Jackson, Evangelia Vlachodimitropoulou, Panicos Shangaris, et al.
American Journal of Hematology|February 1, 2017
New film-coated tablet formulation of deferasirox is well tolerated in patients with thalassemia or lower-risk MDS: Results of the randomized, phase II ECLIPSE studyAli T Taher, Raffaella Origa, Silverio Perrotta, et al.
Journal of Cardiovascular Magnetic Resonance : Official Journal of the Society for Cardiovascular Magnetic Resonance|May 22, 2013
Treatment of heart failure in adults with thalassemia major: response in patients randomised to deferoxamine with or without deferiproneJohn B Porter, John Wood, Nancy Olivieri, et al.
Journal of Magnetic Resonance Imaging : JMRI|August 31, 2007
Myocardial tissue characterization and the role of chronic anemia in sickle cell cardiomyopathyMark A Westwood, Farrukh Shah, Lisa J Anderson, et al.
Blood|May 3, 2015
Effects of deferasirox-deferoxamine on myocardial and liver iron in patients with severe transfusional iron overloadYesim Aydinok, Antonis Kattamis, M Domenica Cappellini, et al.
Annals of Hematology|June 19, 2013
Deferasirox effectively reduces iron overload in non-transfusion-dependent thalassemia (NTDT) patients: 1-year extension results from the THALASSA studyAli T Taher, John B Porter, Vip Viprakasit, et al.
Pageof 13

Showing results (81-90 of 125) with videos related to

Sort By:
Pageof 13
British Journal of Haematology|September 13, 2014
Defining serum ferritin thresholds to predict clinically relevant liver iron concentrations for guiding deferasirox therapy when MRI is unavailable in patients with non-transfusion-dependent thalassaemiaAli T Taher, John B Porter, Vip Viprakasit, et al.
Health and Quality of Life Outcomes|November 21, 2018
Patient-reported outcomes from a randomized phase II study of the deferasirox film-coated tablet in patients with transfusion-dependent anemiasAli T Taher, Raffaella Origa, Silverio Perrotta, et al.
European Journal of Haematology|January 28, 2014
Approaching low liver iron burden in chelated patients with non-transfusion-dependent thalassemia: the safety profile of deferasiroxAli T Taher, John B Porter, Vip Viprakasit, et al.
American Journal of Hematology|October 28, 2014
Sustained improvements in myocardial T2* over 2 years in severely iron-overloaded patients with beta thalassemia major treated with deferasirox or deferoxamineDudley J Pennell, John B Porter, Antonio Piga, et al.
Scientific Reports|February 28, 2017
Non-invasive MRI biomarkers for the early assessment of iron overload in a humanized mouse model of β-thalassemiaLaurence H Jackson, Evangelia Vlachodimitropoulou, Panicos Shangaris, et al.
American Journal of Hematology|February 1, 2017
New film-coated tablet formulation of deferasirox is well tolerated in patients with thalassemia or lower-risk MDS: Results of the randomized, phase II ECLIPSE studyAli T Taher, Raffaella Origa, Silverio Perrotta, et al.
Journal of Cardiovascular Magnetic Resonance : Official Journal of the Society for Cardiovascular Magnetic Resonance|May 22, 2013
Treatment of heart failure in adults with thalassemia major: response in patients randomised to deferoxamine with or without deferiproneJohn B Porter, John Wood, Nancy Olivieri, et al.
Journal of Magnetic Resonance Imaging : JMRI|August 31, 2007
Myocardial tissue characterization and the role of chronic anemia in sickle cell cardiomyopathyMark A Westwood, Farrukh Shah, Lisa J Anderson, et al.
Blood|May 3, 2015
Effects of deferasirox-deferoxamine on myocardial and liver iron in patients with severe transfusional iron overloadYesim Aydinok, Antonis Kattamis, M Domenica Cappellini, et al.
Annals of Hematology|June 19, 2013
Deferasirox effectively reduces iron overload in non-transfusion-dependent thalassemia (NTDT) patients: 1-year extension results from the THALASSA studyAli T Taher, John B Porter, Vip Viprakasit, et al.
Pageof 13